Published

Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Journal of psychopharmacology (Oxford, England)
Date: 2022-01-01
Source: PubMed
DOI: 10.1177/02698811211066714
PubMed: 34983261

Authors

Jones GM Nock MK

Watch author

Derived topics and classifications

psilocybin Depression Addiction Chronic Pain Observational Study Safety Observational Study

Citation graph

0 referenced DOIs found in stored source metadata. 4 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Psilocybin and Mental Health Outcomes: Scoping Review with ☸️SAIMSARA2026-06-15 Prevalence and Correlates of Past-Year Psilocybin Use in the United States2026-04-22 Addressing a major interference in the quantification of psilocin in mouse plasma: Development of a validated liquid chromatography tandem mass spectrometry method2024-08-01 Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes.2022-01-01

Related papers

Investigation of Psychedelic Effects in Psychoactive SubstancesClinicalTrials.gov · 2026-02-23 Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2025-10-01 The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy TrainingClinicalTrials.gov · 2025-04-14